{"page_content": "7\nESG Report 2023\nFinancial Performance\nOur strong balance sheet  \nenables focused execution  \non our near- and long-term \npriorities advancing rare  \ndisease therapies.\nIn April 2021, Agios divested its \noncology business for an upfront payment of $1.8 billion in order to focus solely on accelerating and expanding its rare disease portfolio.We invest in ongoing innovation on behalf of \npeople who have few or no treatment options. \nCASH POSITION\n$1.1 billion  \nas of Dec. 31, 2022\nIn alignment with our current business focus, R&D investment numbers reflect the company's rare disease R&D efforts only.3-YEAR R&D INVESTMENT\n$757 .7\u00a0million2022 R&D INVESTMENT\n$279.9 million", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 6, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}